172 related articles for article (PubMed ID: 10522040)
1. Hepatocellular carcinoma developed in a patient with chronic hepatitis C after the disappearance of hepatitis C virus due to interferon therapy.
Inoue M; Ohhira M; Ohtake T; Matsumoto A; Kawashima T; Fujimoto Y; Hasebe C; Ono M; Kohgo Y
Hepatogastroenterology; 1999; 46(28):2554-60. PubMed ID: 10522040
[TBL] [Abstract][Full Text] [Related]
2. Case report: development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha.
Hirashima N; Mizokami M; Orito E; Koide T; Itazu I; Kumada K; Sakakibara K; Kano H; Lau JY
J Gastroenterol Hepatol; 1996 Oct; 11(10):955-8. PubMed ID: 8912134
[TBL] [Abstract][Full Text] [Related]
3. A case of the development of two hepatocellular carcinomas and a cholangiocarcinoma with cirrhosis after elimination of serum hepatitis C virus RNA with interferon therapy.
Nagano K; Fukuda Y; Nakano I; Katano Y; Toyoda H; Ebata M; Morita K; Yokozaki S; Takeuchi M; Hayashi K; Takeda S; Nonami T; Hayakawa T
Hepatogastroenterology; 2000; 47(35):1436-8. PubMed ID: 11100370
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus.
Tamori A; Nishiguchi S; Shiomi S; Hayashi T; Kobayashi S; Habu D; Takeda T; Seki S; Hirohashi K; Tanaka H; Kubo S
Am J Gastroenterol; 2005 Aug; 100(8):1748-53. PubMed ID: 16086711
[TBL] [Abstract][Full Text] [Related]
6. Type C chronic hepatitis with the discovery of a small hepatocellular carcinoma 7 years after successful interferon therapy.
Tomimatsu M; Endo H; Kitazawa M; Iga D; Fujimoto T; Ohkawa S; Kajiyama H; Katagiri S; Harada N; Yamamoto M; Takasaki K
J Gastroenterol; 2003; 38(4):395-8. PubMed ID: 12743782
[TBL] [Abstract][Full Text] [Related]
7. Resected cases of hepatocellular carcinoma detected after interferon therapy for chronic hepatitis C.
Kubo S; Nishiguchi S; Tamori A; Hirohashi K; Tanaka H; Tsukamoto T; Shuto T; Kuroki T; Kinoshita H
Hepatogastroenterology; 2000; 47(34):1100-2. PubMed ID: 11020887
[TBL] [Abstract][Full Text] [Related]
8. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma?
Tanaka K; Sata M; Uchimura Y; Suzuki H; Tanikawa K
Oncol Rep; 1998; 5(1):205-8. PubMed ID: 9458323
[TBL] [Abstract][Full Text] [Related]
9. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
[TBL] [Abstract][Full Text] [Related]
10. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
[TBL] [Abstract][Full Text] [Related]
11. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.
Bargiggia S; Thorburn D; Anderloni A; Ardizzone S; Giorgi A; Bianchi Porro G; Parente F
Aliment Pharmacol Ther; 2005 Aug; 22(3):209-15. PubMed ID: 16091058
[TBL] [Abstract][Full Text] [Related]
12. A patient with hepatitis C-related cirrhosis and hepatocellular carcinoma who was cured with an orthotopic liver transplantation and interferon therapy.
Shibata M; Yanaga K; Morizane T; Yanagawa T; Hirakawa M; Ueno Y; Esquivel CO; Mitamura K
J Gastroenterol; 2003; 38(6):598-602. PubMed ID: 12858850
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.
Makiyama A; Itoh Y; Kasahara A; Imai Y; Kawata S; Yoshioka K; Tsubouchi H; Kiyosawa K; Kakumu S; Okita K; Hayashi N; Okanoue T
Cancer; 2004 Oct; 101(7):1616-22. PubMed ID: 15378504
[TBL] [Abstract][Full Text] [Related]
14. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin.
Yalcin K; Degertekin H; Yildiz F; Kilinc N
J Gastroenterol; 2003; 38(8):796-800. PubMed ID: 14505137
[TBL] [Abstract][Full Text] [Related]
15. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients.
Squadrito G; Pollicino T; Cacciola I; Caccamo G; Villari D; La Masa T; Restuccia T; Cucinotta E; Scisca C; Magazzu D; Raimondo G
Cancer; 2006 Mar; 106(6):1326-30. PubMed ID: 16453330
[TBL] [Abstract][Full Text] [Related]
16. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer.
Ikeda K; Arase Y; Saitoh S; Kobayashi M; Suzuki Y; Suzuki F; Tsubota A; Chayama K; Murashima N; Kumada H
Hepatology; 2000 Aug; 32(2):228-32. PubMed ID: 10915728
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of genotype 1 TT virus infection in patients with chronic hepatitis C and response of TT virus to alpha-interferon.
Nishizawa Y; Tanaka E; Orii K; Rokuhara A; Ichijo T; Yoshizawa K; Kiyosawa K
J Gastroenterol Hepatol; 2000 Nov; 15(11):1292-7. PubMed ID: 11129224
[TBL] [Abstract][Full Text] [Related]
18. Development of well-differentiated hepatocellular carcinoma in large adenomatous hyperplasia after long-term follow-up: a case report.
Midorikawa Y; Ishikawa T; Kubota K; Mori M; Takayama T; Makuuchi M
Hepatogastroenterology; 2002; 49(46):1098-101. PubMed ID: 12143212
[TBL] [Abstract][Full Text] [Related]
19. Interferon can block telomere erosion and in rare cases result in hepatocellular carcinoma development with telomeric repeat binding factor 1 overexpression in chronic hepatitis C.
Igarashi M; Suda T; Hara H; Takimoto M; Nomoto M; Takahashi T; Okoshi S; Kawai H; Mita Y; Waguri N; Aoyagi Y
Clin Cancer Res; 2003 Nov; 9(14):5264-70. PubMed ID: 14614008
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma.
El-Bassiouni A; Nosseir M; Zoheiry M; El-Ahwany E; Ghali A; El-Bassiouni N
APMIS; 2006 Jun; 114(6):420-7. PubMed ID: 16856963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
